Nkarta, Inc. (NKTX)
2.26
+0.04
(+1.80%)
USD |
NASDAQ |
Oct 09, 16:00
2.26
0.00 (0.00%)
After-Hours: 19:59
Nkarta Enterprise Value : 49.78M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 49.78M |
| October 07, 2026 | 53.36M |
| October 06, 2026 | 56.22M |
| October 05, 2026 | 71.98M |
| October 02, 2026 | 75.20M |
| October 01, 2026 | 74.13M |
| September 30, 2026 | 78.43M |
| September 29, 2026 | 78.43M |
| September 28, 2026 | 82.01M |
| September 25, 2026 | 87.74M |
| September 24, 2026 | 94.90M |
| September 23, 2026 | 88.45M |
| September 22, 2026 | 102.06M |
| September 21, 2026 | 97.05M |
| September 18, 2026 | 93.47M |
| September 17, 2026 | 92.03M |
| September 16, 2026 | 96.33M |
| September 15, 2026 | 97.05M |
| September 14, 2026 | 99.91M |
| September 11, 2026 | 99.20M |
| September 10, 2026 | 92.03M |
| September 09, 2026 | 99.20M |
| September 08, 2026 | 122.11M |
| September 04, 2026 | 99.91M |
| September 03, 2026 | 90.60M |
| Date | Value |
|---|---|
| September 02, 2026 | 88.81M |
| September 01, 2026 | 84.15M |
| August 31, 2026 | 84.87M |
| August 28, 2026 | 88.45M |
| August 27, 2026 | 87.74M |
| August 26, 2026 | 79.14M |
| August 25, 2026 | 84.87M |
| August 24, 2026 | 76.28M |
| August 21, 2026 | 81.29M |
| August 20, 2026 | 67.68M |
| August 19, 2026 | 72.70M |
| August 18, 2026 | 63.38M |
| August 17, 2026 | 64.82M |
| August 14, 2026 | 57.65M |
| August 13, 2026 | 55.51M |
| August 12, 2026 | 61.95M |
| August 11, 2026 | 57.65M |
| August 10, 2026 | 66.97M |
| August 07, 2026 | 63.38M |
| August 06, 2026 | 54.79M |
| August 05, 2026 | 48.34M |
| August 04, 2026 | 52.64M |
| August 03, 2026 | 44.76M |
| July 31, 2026 | 40.47M |
| July 30, 2026 | 44.76M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.488B |
| Alnylam Pharmaceuticals, Inc. | 29.71B |
| Savara, Inc. | 849.45M |
| Vericel Corp. | 1.982B |
| Biogen, Inc. | 39.33B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -40.37M |
| Total Expenses (Quarterly) | 40.37M |
| EPS Diluted (Quarterly) | -0.5419 |
| Earnings Yield | -69.92% |
| Normalized Earnings Yield | -73.27 |